Literature DB >> 8023853

A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals.

D Bourn1, S A Carter, D G Evans, J Goodship, H Coakham, T Strachan.   

Abstract

We have sought mutations in the recently identified neurofibromatosis type 2 (NF2) tumor-suppressor gene in a large panel of NF2 patients, using PCR-based SSCP and heteroduplex analysis, followed by cloning and sequencing of appropriate PCR products. Two unrelated NF2 patients were found to have identical nonsense mutations caused by a C-to-T transition in a CpG dinucleotide that is a potential mutational hot spot in the NF2 tumor-suppressor gene. Unexpectedly, the two individuals had widely different clinical phenotypes, representing the severe Wishart and mild Gardner clinical subtypes. Analysis of DNA samples from different tissues of the mildly affected patient suggests that he is a somatic mosaic for the mutation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8023853      PMCID: PMC1918220     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  22 in total

1.  Rapid detection of single base mismatches as heteroduplexes on Hydrolink gels.

Authors:  J Keen; D Lester; C Inglehearn; A Curtis; S Bhattacharya
Journal:  Trends Genet       Date:  1991-01       Impact factor: 11.639

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

3.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

4.  Molecular basis of base substitution hotspots in Escherichia coli.

Authors:  C Coulondre; J H Miller; P J Farabaugh; W Gilbert
Journal:  Nature       Date:  1978-08-24       Impact factor: 49.962

5.  Cytovillin, a microvillar Mr 75,000 protein. cDNA sequence, prokaryotic expression, and chromosomal localization.

Authors:  O Turunen; R Winqvist; R Pakkanen; K H Grzeschik; T Wahlström; A Vaheri
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

6.  Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus.

Authors:  M Sanson; C Marineau; C Desmaze; M Lutchman; M Ruttledge; C Baron; S Narod; O Delattre; G Lenoir; G Thomas
Journal:  Hum Mol Genet       Date:  1993-08       Impact factor: 6.150

7.  Molecular cloning of protein 4.1, a major structural element of the human erythrocyte membrane skeleton.

Authors:  J Conboy; Y W Kan; S B Shohet; N Mohandas
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Mutagenic deamination of cytosine residues in DNA.

Authors:  B K Duncan; J H Miller
Journal:  Nature       Date:  1980-10-09       Impact factor: 49.962

9.  cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1.

Authors:  K L Gould; A Bretscher; F S Esch; T Hunter
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

10.  Rapid phosphorylation and reorganization of ezrin and spectrin accompany morphological changes induced in A-431 cells by epidermal growth factor.

Authors:  A Bretscher
Journal:  J Cell Biol       Date:  1989-03       Impact factor: 10.539

View more
  17 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma.

Authors:  D R Lohmann; M Gerick; B Brandt; U Oelschläger; B Lorenz; E Passarge; B Horsthemke
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

Review 3.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

4.  Eleven novel mutations in the NF2 tumour suppressor gene.

Authors:  D Bourn; G Evans; S Mason; S Tekes; L Trueman; T Strachan
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

5.  Neurofibromatosis 2 invasion of the internal auditory canal wall: clinical significance.

Authors:  Joni Doherty; John L Go; Fred H Linthicum
Journal:  Otol Neurotol       Date:  2014-10       Impact factor: 2.311

6.  Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling.

Authors:  K C Sippel; R E Fraioli; G D Smith; M E Schalkoff; J Sutherland; B L Gallie; T P Dryja
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.

Authors:  D M Parry; M M MacCollin; M I Kaiser-Kupfer; K Pulaski; H S Nicholson; M Bolesta; R Eldridge; J F Gusella
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

8.  Somatic mosaicism in a patient with neurofibromatosis type 1.

Authors:  S D Colman; S A Rasmussen; V T Ho; C R Abernathy; M R Wallace
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

9.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

Authors:  D G Evans; L Trueman; A Wallace; S Collins; T Strachan
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

10.  A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2.

Authors:  L Kluwe; V F Mautner
Journal:  Hum Genet       Date:  1996-02       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.